ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0065

Rheumatoid Arthritis Clinical Care Pathway Implementation: A Step Towards Improved Outcomes and Value-Based Care

Tarun Sharma1, paul lebovitz1, chetan rajput2, Lori Mcaninch3, ellen Kraemer3, izabela Stanescu3, adam dore1, joseph ahearn3 and Susan Manzi4, 1Allegheny Health Network, Pittsburgh, PA, 2Highmark Health, Pittsburgh, 3Allegheny Health Network, Pittsburgh, 4Allegheny Health Network, Lupus Center of Excellence, Wexford, PA

Meeting: ACR Convergence 2022

Keywords: Administrative Data, Measurement, Outcome measures, Quality Indicators, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Health Services Research Poster I: Lupus, RA, Spondyloarthritis and More

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Care transformation in a chronic illness like RA requires delivery of health care services through a patient-centric care model. Within an integrated delivery and finance system, our first step towards the goal of RA care transformation and a shift to value-based care included implementation of a multi-faceted RA clinical care pathway.

Methods: At the Allegheny Health Network Autoimmunity Institute, RA care transformation efforts started in 2020 Q1 by an expert panel attempting to answer the fundamental question: what does the ideal RA care look like from a patient perspective, and how do we strive to achieve it with every patient encounter? Consensus based best practices were derived and a RA care pathway was designed with 3 major focus areas: alignment on outcomes that matter, such as disease activity, functional and quality measures (definition phase, 2020 Q1), followed by process design and implementation of prospective data capture tools (collection phase, 2020 Q2-3), and ultimately measurements with linkage to population health and value-based care (metric dashboards, 2020 Q3 – current) (Figure 1). The primary aim of this study was to measure adherence to the RA care pathway best practices (table 1, target 80%), and to identify opportunities for improvement in the process. Secondary aim was to evaluate whether pathway adherence leads to improved clinical outcomes compared to usual care. A major patient-centric aspect of our care pathway included the focus on productive interactions between an informed, activated patient (via patient education), and a prepared, proactive practice team (RA nurse navigator, clinical pharmacist, behavioral health specialist, registered dietician, and social worker). Quarterly performance metrics were transparently shared at monthly faculty and staff meetings.

Results: Currently the RA care pathway includes 455 patients, including 55 patients that were newly diagnosed with RA since launching pathways. Eight patients were excluded due to relocation or loss of follow up. Patient demographics and overall dashboard metrics are detailed in table 1. Clinical Disease Activity Index (CDAI) measurement and proportion of patients in remission/low disease activity were higher compared to upon pathway entry and compared to usual care sites (Figure 2). Performance was noted to be below the target especially in the prevention/safety performance metrics, therefore an immunization campaign was launched at our clinical sites in 2022 Q1 with help of our clinical pharmacist, and efforts on staff re-education to better capture SDOH domains are underway.

Conclusion: We found that routine measurement of RA best practice metrics could help identify opportunities for care improvement. Implementation of a RA Care Pathway comprising of management best practices and a team-based care approach may be superior to usual care. We have implemented SDOH re-education and immunization campaigns in an effort to improve performance in the prevention and safety domains, and introduced nursing touchpoints between visits for patients with moderate-severe RA. Longitudinal data collection, and including patient experience, cost, and utilization data are among our next steps towards value-based care.

Supporting image 1

Figure 1. Three Focus Areas of the RA Care Pathway Initiative

Supporting image 2

Table 1. RA Care Pathway Performance Metrics

Supporting image 3

Figure 2. Comparison of Trends of CDAI Completion at Visits and Remission/Low Disease Activity in Patients in RA Care Pathway vs Usual Care


Disclosures: T. Sharma, None; p. lebovitz, None; c. rajput, None; L. Mcaninch, None; e. Kraemer, None; i. Stanescu, None; a. dore, AbbVie/Abbott, Exagen; j. ahearn, None; S. Manzi, AstraZeneca, GlaxoSmithKline (GSK), Exagen Diagnostics Inc, AbbVie, HGS, Cugene, Lilly, UCB Advisory Board, Lupus Foundation of America.

To cite this abstract in AMA style:

Sharma T, lebovitz p, rajput c, Mcaninch L, Kraemer e, Stanescu i, dore a, ahearn j, Manzi S. Rheumatoid Arthritis Clinical Care Pathway Implementation: A Step Towards Improved Outcomes and Value-Based Care [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/rheumatoid-arthritis-clinical-care-pathway-implementation-a-step-towards-improved-outcomes-and-value-based-care/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/rheumatoid-arthritis-clinical-care-pathway-implementation-a-step-towards-improved-outcomes-and-value-based-care/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology